Zusammenfassung
Antipsychotischen Substanzen kommt in der Behandlung bipolarer affektiver Störungen
ein bedeutender klinischer Stellenwert zu. Trotz des gut dokumentierten antimanischen
Effektes klassischer Antipsychotika ist der Einsatz dieser Substanzen, nicht zuletzt
wegen des weitgehenden Fehlens stimmungsstabilisierender Eigenschaften und des erhöhten
Risikos für Spätdyskinesien bei affektiven Patienten, mit einer Reihe von Nachteilen
verbunden. Mit Entwicklung der neuen, sog. atypischen Antipsychotika ist die Pharmakotherapie
der bipolaren Störung um vielversprechende Dimensionen erweitert worden. Gut untersucht
wurden die thymoleptischen Eigenschaften von Clozapin, Risperidon und Olanzapin. Für
Clozapin und Olanzapin werden ausgeprägtere antimanische als antidepressive Eigenschaften
vermutet, Risperidon hingegen dürfte eine stärkere antidepressive als antimanische
Wirkkomponente aufweisen. Dieser Artikel bietet einen Überblick über die vorliegenden
Studien zur Wirksamkeit atypischer Antipsychotika in der Indikation der bipolaren
Störung, darüber hinaus werden mögliche Arzneimittelinteraktionen zwischen Antipsychotika
und anderen stimmungsstabilisierenden Pharmaka auf Basis des Cytochrom-P450-Systems
diskutiert. Zusammenfassend ist anzunehmen, dass atypische Antipsychotika wertvolle
Optionen in der Pharmakotherapie der bipolaren Störung darstellen. Zur Evaluierung
des Stellenwertes einzelner Substanzen in dieser Indikation bedarf es jedoch weiterer
kontrollierter Untersuchungen.
Abstract
Antipsychotics are commonly used in the treatment of bipolar affective disorder. The
use of conventional antipsychotic agents, though effective as antimanic agents, is
associated with a number of limitations such as their acute side effect profile and
their unsufficient mood stabilizing activity. In addition, exposure to conventional
neuroleptics poses a risk for the development of tardive dyskinesia, especially in
mood disorder patients. Growing evidence suggests that the novel, so-called atypical
neuroleptics may offer a number of advantages in the treatment of bipolar disorder,
including their thymoleptic activity and minimal risk for acute and long-term extraypyramidal
symptoms. Clinical experience with clozapine and olanzapine as mood stabilizers suggests
greater antimanic than antidepressant properties, while risperidone may have greater
antidepressant properties with some liability for triggering or exacerbating mania.
The mood stabilizing properties of further atypical drugs are currently under investigation.
This review focuses on the use of atypical antipsychotics in the treatment of bipolar
disorder. We also present an overview concerning potential pharmakokinetic interactions
based on the cytochrome P450 enzyme system when antipsychotics are combined with other
mood stabilizing compounds. In conclusion, atypical antipsychotics should come to
play an increasingly important role in the acute and long-term management of bipolar
disorder, but there is a clear need for further controlled trials in this indication.
Literatur
- 1 Goodwin F K, Jamison K R. Manic-Depressive Illness. New York: Oxford University
Press 1990
- 2
Prien R F, Gelenberg A J.
Alternatives to lithium for preventive treatment of bipolar disorder.
Am J Psychiatry.
1989;
46(7)
840-848
- 3
Post R M, Ketter T A, Denicoff K, Pazzaglia P J, Leverich G S, Marangell L B, Callahan A M,
George M S, Frye M A.
The place of anticonvulsant therapy in bipolar illness.
Psychopharmacology.
1996;
128(2)
115-129
- 4
Himmelhoch J M, Garfinkel M E.
Sources of lithium resistance in mixed mania.
Psychopharmacol Bull.
1986;
22(3)
613-620
- 5
Dunner D L, Fieve R R.
Clinical factors in lithium carbonate prophylaxis failure.
Arch Gen Psychiatry.
1974;
30(2)
229-233
- 6
Gitlin M J, Swendsen J, Heller T L, Hammen C.
Relapse and impairment in bipolar disorder.
Am J Psychiatry.
1995;
152(11)
1635-1640
- 7
Denicoff K D, Smith-Jackson E E, Disney E R, Ali S O, Leverich G S, Post R M.
Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in
bipolar disorder.
J Clin Psychiatry.
1997;
58(11)
470-478
- 8
Sernyak M J, Godleski L S, Griffin R A, Mazure C M, Woods S W.
Chronic neuroleptic exposure in bipolar outpatients.
J Clin Psychiatry.
1997;
58(5)
193-195
- 9
Sernyak M J, Woods S W.
Chronic neuroleptic use in manic-depressive illness.
Psychopharmacol Bull.
1993;
29(3)
375-381
- 10
Verdoux H, Gonzales B, Takei N, Bourgeois M.
A survey of prescribing practice of antipsychotic maintenance treatment for manic-depressive
outpatients.
J Affect Disord.
1996;
38(2 - 3)
81-87
- 11
Johnson G, Gershon S, Burdock E I, Floyd A, Hekimian L.
Comparative effects of lithium and chlorpromazine in the treatment of acute manic
states.
Br J Psychiatry.
1971;
119(550)
267-276
- 12
Spring G, Schweid D, Gray C, Steinberg J, Horwitz M.
A double-blind comparison of lithium and chlorpromazine in the treatment of manic
states.
Am J Psychiatry.
1970;
126(9)
1306-1310
- 13
Platman S R.
A comparison of lithium carbonate and chlorpromazine in mania.
Am J Psychiatry.
1970;
127(3)
351-353
- 14
Prien R F, Caffey Jr E M, Klett C J.
A comparison of lithium carbonate and chlorpromazine in the treatment of excited schizo-affectives.
Report of the Veterans Administration and National Institute of Mental Health collaborative
study group.
Arch Gen Psychiatry.
1972;
27(2)
182-189
- 15
Shopsin B, Gershon S, Thompson H, Collins P.
Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine,
and haloperidol.
Arch Gen Psychiatry.
1975;
32(1)
34-42
- 16
McElroy S L, Keck P E, Stanton S P, Tugrul K C, Bennett J A, Strakowski S M.
A randomized comparison of divalproex oral loading versus haloperidol in the initial
treatment of acute psychotic mania.
J Clin Psychiatry.
1996;
57(4)
142-146
- 17 Grossi E, Saccetti E, Vita A. Carbamazepine vs. chlorpromazine in manics: a double
blind trial. In: Emrich HM, Okuma T, Muller AA (Eds.) Anticonvulsants in affective
disorders Amsterdam, The Netherlands: Excerpta Medica 1984: 177-187
- 18
Okuma T, Inanaga K, Otsuki S, Sarai K, Takahashi R, Hazama H, Mori A, Watanabe M.
Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind
controlled study.
Psychopharmacology.
1979;
66(3)
211-217
- 19
Janicak P G, Bresnahan D B, Sharma R, Davis J M, Comaty J E, Malinick C.
A comparison of thiothixene with chlorpromazine in the treatment of mania.
J Clin Psychopharmacol.
1988;
8(1)
33-37
- 20
Tohen M, Zarate Jr C A.
Antipsychotic agents and bipolar disorder.
J Clin Psychiatry.
1998;
59 Suppl 1
38-48
- 21
Ahlfors U G, Baastrup P C, Dencker S J, Elgen K, Lingjaerde O, Pedersen V, Schou M,
Aaskoven O.
Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium.
Acta Psychiatr Scand.
1981;
64(3)
226-237
- 22
Peselow E D, Fieve R R, Difiglia C, Sanfilipo M P.
Lithium prophylaxis of bipolar illness. The value of combination treatment.
Br J Psychiatry.
1994;
164(2)
208-214
- 23
Cole J O, Gardos G, Boling L A, Marby D, Haskell D, Moore P.
Early dyskinesia-vulnerability.
Psychopharmacology.
1992;
107(4)
503-510
- 24
Gardos G, Teicher M H, Lipinski Jr J F, Matthews J D, Morrison L, Conley C, Cole J O.
Quantitative assessment of psychomotor activity in patients with neuroleptic-induced
akathisia.
Prog Neuropsychopharmacol Biol Psychiatry.
1992;
16(1)
27-37
- 25
Davis K L, Berger P A, Hollister L E.
Tardive dyskinesia and depressive illness.
Psychopharmacol Commun.
1976;
2(2)
125-130
- 26
Rosenbaum A H, Niven R G, Hanson N P, Swanson D W.
Tardive dyskinesia: relationship with a primary affective disorder.
Dis Nerv Syst.
1977;
38(6)
423-427
- 27 Jeste D V, Wyatt R J. Understanding and treating tardive dyskinesia. New York:
Guilford Press 1982
- 28
Glenthoj B, Hemmingsen R, Allerup P, Bolwig T G.
Intermittent versus continuous neuroleptic treatment in a rat model.
Eur J Pharmacol.
1990;
190(3)
275-286
- 29
Keck Jr P E, McElroy S L, Strakowski S M, Soutullo C A.
Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia.
J Clin Psychiatry.
2000;
61 Suppl 4
33-8
- 30
Yassa R, Nair V, Schwartz G.
Tardive dyskinesia and the primary psychiatric diagnosis.
Psychosomatics.
1984;
25(2)
135-138
- 31
Yassa R, Ghadirian A M, Schwartz G.
Prevalence of tardive dyskinesia in affective disorder patients.
J Clin Psychiatry.
1983;
44(11)
410-412
- 32
Mukherjee S, Rosen A M, Caracci G, Shukla S.
Persistent tardive dyskinesia in bipolar patients.
Arch Gen Psychiatry.
1986;
43(4)
342-346
- 33
Lal K P, Saxena S, Mohan D.
Tardive dystonia alternating with mania.
Biol Psychiatry.
1988;
23(3)
312-316
- 34
Sachdev P S.
Depression-dependent exacerbation of tardive dyskinesia.
Br J Psychiatry.
1989;
155
253-255
- 35
Wegner J T, Catalano F, Gibralter J, Kane J M.
Schizophrenics with tardive dyskinesia. Neuropsychological deficit and family psychopathology.
Arch Gen Psychiatry.
1985;
42(9)
860-865
- 36
Wegner J T, Kane J M, Weinhold P, Woerner M, Kinon B, Lieberman J.
Cognitive impairment in tardive dyskinesia.
Psychiatry Res.
1985;
16(4)
331-317
- 37
Hilger E, Kasper S.
Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders.
Wien Klin Wochenschr.
2000;
112(24)
1031-1038
- 38
Ghaemi S N.
New treatments for bipolar disorder: the role of atypical neuroleptic agents.
J Clin Psychiatry.
2000;
61 Suppl 14
33-42
- 39
Brown E S, Thomas N R, Carmody T, Mahadi S, Nejtek V A.
Atypical antipsychotics in bipolar and schizoaffective disorders.
Pharmacopsychiatry.
2001;
34(2)
80-81
- 40
Soares J C.
Recent advances in the treatment of bipolar mania, depression, mixed states, and rapid
cycling.
Int Clin Psychopharmacol.
2000;
15(4)
183-196
- 41
Keck Jr P E, McElroy S L, Strakowski S M.
Anticonvulsants and antipsychotics in the treatment of bipolar disorder.
J Clin Psychiatry.
1998;
59 Suppl 6
74-81
- 42
Gelenberg A J, Hopkins H S.
Antipsychotics in bipolar disorder.
J Clin Psychiatry.
1996;
57 Suppl 9
49-52
- 43
Tohen M, Jacobs T G, Feldman P D.
Onset of action of antipsychotics in the treatment of mania.
Bipolar Disord.
2000;
2(2)
261-268
- 44
Zarate Jr C A, Tohen M, Baldessarini R J.
Clozapine in severe mood disorders.
J Clin Psychiatry.
1995;
56(9)
411-417
- 45
Frye M A, Ketter T A, Altshuler L L, Denicoff K, Dunn R T, Kimbrell T A, Cora-Locatelli G,
Post R M.
Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics.
J Affect Disord.
1998;
48(2 - 3)
91-104
- 46
Battegay R, Cotar B, Fleischhauer J, Rauchfleisch U.
Results and side effects of treatment with clozapine (leponex R).
Compr Psychiatry.
1977;
18(5)
423-428
- 47
Leppig M, Bosch B, Naber D, Hippius H.
Clozapine in the treatment of 121 out-patients.
Psychopharmacology (Berl).
1989;
99
77-79
- 48
Naber D, Hippius H.
The European experience with use of clozapine.
Hosp Community Psychiatry.
1990;
41(8)
886-890
- 49
Ciapparelli A, Dell'Osso L, Pini S, Chiavacci M C, Fenzi M, Cassano G B.
Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic
bipolar disorder: a 24-month naturalistic study.
J Clin Psychiatry.
2000;
61(5)
329-334
- 50
McElroy S L, Dessain E C, Pope Jr H G, Cole J O, Keck Jr P E, Frankenberg F R, Aizley H G,
O'Brien S.
Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder,
and schizophrenia.
J Clin Psychiatry.
1991;
52(10)
411-414
- 51
Zarate Jr C A, Tohen M, Banov M D, Weiss M K, Cole J O.
Is clozapine a mood stabilizer?.
J Clin Psychiatry.
1995;
56(3)
108-112
- 52
Suppes T, Rush A J, Webb A, Carmody T, Kraemer H.
A one year randomized trial of clozapine vs. usual care in bipolar I patients.
Biol Psychiatry.
1996;
39
531
- 53
Calabrese J R, Meltzer H Y, Markovitz P J.
Clozapine prophylaxis in rapid cycling bipolar disorder.
J Clin Psychopharmacol.
1991;
11(6)
396-397
- 54
Green A I, Tohen M, Patel J K, Banov M, DuRand C, Berman I, Chang H, Zarate Jr C,
Posener J, Lee H, Dawson R, Richards C, Cole J O, Schatzberg A F.
Clozapine in the treatment of refractory psychotic mania.
Am J Psychiatry.
2000;
157(6)
982-998
- 55
Kimmel S E, Calabrese J R, Woyshville M J, Meltzer H Y.
Clozapine in treatment-refractory mood disorders.
J Clin Psychiatry.
1994;
55 Suppl B
91-93
- 56
Calabrese J R, Kimmel S E, Woyshville M J, Rapport D J, Faust C J, Thompson P A, Meltzer H Y.
Clozapine for treatment-refractory mania.
Am J Psychiatry.
1996;
153(6)
759-764
- 57
Suppes T, McElroy S L, Gilbert J, Dessain E C, Cole J O.
Clozapine in the treatment of dysphoric mania.
Biol Psychiatry.
1992;
32(3)
270-280
- 58
Frye M A, Altshuler L L, Bitran J A.
Clozapine in rapid cycling bipolar disorder.
J Clin Psychopharmacol.
1996;
16(1)
87-90
- 59
Suppes T, Phillips K A, Judd C R.
Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: a report of three
cases.
Biol Psychiatry.
1994;
36(5)
338-340
- 60
Banov M D, Zarate Jr C A, Tohen M, Scialabba D, Wines Jr J D, Kolbrener M, Kim J W,
Cole J O.
Clozapine therapy in refractory affective disorders: polarity predicts response in
long-term follow-up.
J Clin Psychiatry.
1994;
55(7)
295-300
- 61
Alvir J M, Lieberman J A, Safferman A Z, Schwimmer J L, Schaaf J A.
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.
N Engl J Med.
1993;
329(3)
162-167
- 62
Miller D D.
Review and management of clozapine side effects.
J Clin Psychiatry.
2000;
61 Suppl 8
14-17
- 63
Denney D, Stevens J R.
Clozapine and seizures.
Biol Psychiatry.
1995;
37(7)
427-433
- 64
Risby E D, Epstein C M, Jewart R D, Nguyen B V, Morgan W N, Risch S C, Thrivikraman K V,
Lewine R L.
Clozapine-induced EEG abnormalities and clinical response to clozapine.
J Neuropsychiatry Clin Neurosci.
1995;
7(4)
466-470
- 65
Sajatovic M, DiGiovanni S K, Bastani B, Hattab H, Ramirez L F.
Risperidone therapy in treatment refractory acute bipolar and schizoaffective mania.
Psychopharmacol Bull.
1996;
32(1)
55-61
- 66
Schaffer C B, Schaffer L C.
The use of risperidone in the treatment of bipolar disorder.
J Clin Psychiatry.
1996;
57(3)
136
- 67
Jacobsen F M.
Risperidone in the treatment of affective illness and obsessive-compulsive disorder.
J Clin Psychiatry.
1995;
56(9)
423-429
- 68
Schweitzer I.
Does risperidone have a place in the treatment of nonschizophrenic patients?.
Int Clin Psychopharmacol.
2001;
16(1)
1-19
- 69
Tohen M, Zarate Jr C A, Centorrino F, Hegarty J I, Froeschl M, Zarate S B.
Risperidone in the treatment of mania.
J Clin Psychiatry.
1996;
57(6)
249-253
- 70
Roose K, Gelders Y, Heylen S.
Risperidone (R64 766) in psychotic patients. A first clinical therapeutic exploration.
Acta Psychiatr Belg.
1988;
88(3)
233-241
- 71
McIntyre R, Young L T, Hasey G, Patelis-Siotis I, Jones B D.
Risperidone treatment of bipolar disorder.
Can J Psychiatry.
1997;
42(1)
88-90
- 72
Lane H Y, Chiu W C, Chang W H.
Risperidone monotherapy for mania and depression.
Am J Psychiatry.
1999;
156(7)
1115
- 73
Goodnick P J.
Risperidone treatment of refractory acute mania.
J Clin Psychiatry.
1995;
56(9)
431-432
- 74
Ghaemi S N, Sachs G S, Baldassano C F, Truman C J.
Acute treatment of bipolar disorder with adjunctive risperidone in outpatients.
Can J Psychiatry.
1997;
42(2)
196-199
- 75
Singh A N, Catalan J.
Risperidone in HIV-related manic psychosis.
Lancet.
1994;
344(8928)
1029-1030
- 76
Madhusoodanan S, Brenner R, Araujo L, Abaza A.
Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective
disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series.
J Clin Psychiatry.
1995;
56(11)
514-518
- 77
Licht R W, Bysted M, Christensen H.
Fixed-dosed risperidone in mania: an open experimental trial.
Int Clin Psychopharmacol.
2001;
16(2)
103-110
- 78
Segal J, Berk M, Brook S.
Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized
controlled trial.
Clin Neuropharmacol.
1998;
21(3)
176-180
- 79
Ghaemi S N, Sachs G S.
Long-term risperidone treatment in bipolar disorder: 6-month follow.
Int Clin Psychopharmacol.
1997;
12(6)
333-338
- 80
Vieta E, Gasto C, Colom F, Martinez A, Otero A, Vallejo J.
Treatment of refractory rapid cycling bipolar disorder with risperidone.
J Clin Psychopharmacol.
1998;
18(2)
172-174
- 81
Dwight M M, Keck Jr P E, Stanton S P, Strakowski S M, McElroy S L.
Antidepressant activity and mania associated with risperidone treatment of schizoaffective
disorder.
Lancet.
1994;
344(8921)
554-555
- 82
Keck Jr P E, Wilson D R, Strakowski S M, McElroy S L, Kizer D L, Balistreri T M, Holtman H M,
DePriest M.
Clinical predictors of acute risperidone response in schizophrenia, schizoaffective
disorder, and psychotic mood disorders.
J Clin Psychiatry.
1995;
56(10)
466-470
- 83
Hillert A, Maier W, Wetzel H, Benkert O.
Risperidone in the treatment of disorders with a combined psychotic and depressive
syndrome - a functional approach.
Pharmacopsychiatry.
1992;
25(5)
213-217
- 84
Aubry J M, Simon A E, Bertschy G.
Possible induction of mania and hypomania by olanzapine or risperidone: a critical
review of reported cases.
J Clin Psychiatry.
2000;
61(9)
649-655
- 85
Lane H Y, Lin Y C, Chang W H.
Mania induced by risperidone: dose related?.
J Clin Psychiatry.
1998;
59(2)
85-86
- 86
Schnierow B J, Graeber D A.
Manic symptoms associated with initiation of risperidone.
Am J Psychiatry.
1996;
153(9)
1235-1236
- 87
Tomlinson W C.
Respiridone and mania.
Am J Psychiatry.
1996;
153(1)
132-133
- 88
Khouzam H R, El-Gabalawi F.
Treatment of bipolar I disorder in an adolescent with olanzapine.
J Child Adolesc Psychopharmacol.
2000;
10(2)
147-151
- 89
Soutullo C A, Sorter M T, Foster K D, McElroy S L, Keck P E.
Olanzapine in the treatment of adolescent acute mania: a report of seven cases.
J Affect Disord.
1999;
53(3)
279-283
- 90
Weisler R H, Ahearn E P, Davidson J R, Wallace C D.
Adjunctive use of olanzapine in mood disorders: five case reports.
Ann Clin Psychiatry.
1997;
9(4)
259-262
- 91
Goodnick P J, Barrios C A.
Use of olanzapine in non-psychotic psychiatric disorders.
Expert Opin Pharmacother.
2001;
2(4)
667-680
- 92
McElroy S L, Frye M, Denicoff K, Altshuler L, Nolen W, Kupka R, Suppes T, Keck Jr P E,
Leverich G S, Kmetz G F, Post R M.
Olanzapine in treatment-resistant bipolar disorder.
J Affect Disord.
1998;
49(2)
119-122
- 93
Ananth J.
Is olanzapine a mood stabilizer?.
Can J Psychiatry.
1999;
44(9)
927-928
- 94
Guille C, Sachs G S, Ghaemi S N.
A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment
of bipolar disorder.
J Clin Psychiatry.
2000;
61(9)
638-642
- 95
Berk M, Ichim L, Brook S.
Olanzapine compared to lithium in mania: a double-blind randomized controlled trial.
Int Clin Psychopharmacol.
1999;
14(6)
339-343
- 96 Tohen M, Zarate C A, Centorrino F, Hegarty J, Zarate S M. Olanzapine versus haloperidol
in the treatment of schizoaffective bipolar patients. San Diego, California :Annual
Meeting of the Amerian Psychiatric Association May 17 - 22, 1997
- 97
Sharma V, Pistor L.
Treatment of bipolar mixed state with olanzapine.
J Psychiatry Neurosci.
1999;
24(1)
40-44
- 98
Zullino D, Baumann P.
Olanzapine for mixed episodes of bipolar disorder.
J Psychopharmacol.
1999;
13(2)
198
- 99
Ketter T A, Winsberg M E, DeGolia S G, Dunai M, Tate D L, Strong C M.
Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states.
J Clin Psychiatry.
1998;
59(2)
83-85
- 100
Tohen M, Jacobs T G, Grundy S L, McElroy S L, Banov M C, Janicak P G, Sanger T, Risser R,
Zhang F, Toma V, Francis J, Tollefson G D, Breier A.
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled
study. The Olanzapine HGGW Study Group.
Arch Gen Psychiatry.
2000;
57(9)
841-849
- 101
Tohen M, Sanger T M, McElroy S L, Tollefson G D, Chengappa K N, Daniel D G, Petty F,
Centorrino F, Wang R, Grundy S L, Greaney M G, Jacobs T G, David S R, Toma V.
Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.
Am J Psychiatry.
1999;
156(5)
702-709
- 102
Sanger T M, Grundy S L, Gibson P J, Namjoshi M A, Greaney M G, Tohen M F.
Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label
continuation phase study.
J Clin Psychiatry.
2001;
62(4)
273-281
- 103
Zarate Jr C A, Narendran R, Tohen M, Greaney J J, Berman A, Pike S, Madrid A.
Clinical predictors of acute response with olanzapine in psychotic mood disorders.
J Clin Psychiatry.
1998;
59(1)
24-28
- 104
Ghaemi S N, Cherry E L, Katzow J A, Goodwin F K.
Does olanzapine have antidepressant properties? A retrospective preliminary study.
Bipolar Disord.
2000;
2(3)
196-199
- 105
Fitz-Gerald M J, Pinkofsky H B, Brannon G, Dandridge E, Calhoun A.
Olanzapine-induced mania.
Am J Psychiatry.
1999;
156(7)
1114
- 106
Lindenmayer J P, Klebanov R.
Olanzapine-induced manic-like syndrome.
J Clin Psychiatry.
1998;
59(6)
318-319
- 107
Allison D B, Casey D E.
Antipsychotic-induced weight gain: a review of the literature.
J Clin Psychiatry.
2001;
62 Suppl 7
22-31
- 108
Harada T, Otsuki S.
Antimanic effect of zotepine.
Clin Ther.
1986;
8(4)
406-414
- 109
Wolfersdorf M, Konig F, Straub R.
Pharmacotherapy of delusional depression: experience with combinations of antidepressants
with the neuroleptics zotepine and haloperidol.
Neuropsychobiology.
1994;
29(4)
189-193
- 110
Ghaemi S N, Katzow J J.
The use of quetiapine for treatment-resistant bipolar disorder: a case series.
Ann Clin Psychiatry.
1999;
11(3)
137-140
- 111
Dunayevich E, Strakowski S M.
Quetiapine for treatment-resistant mania.
Am J Psychiatry.
2000;
157(8)
1341
- 112
Zarate Jr C A, Rothschild A, Fletcher K E, Madrid A, Zapatel J.
Clinical predictors of acute response with quetiapine in psychotic mood disorders.
J Clin Psychiatry.
2000;
61(3)
185-189
- 113
Ghaemi S N.
New treatments for bipolar disorder: the role of atypical neuroleptic agents.
J Clin Psychiatry.
2000;
61 Suppl 14
33-42
- 114
McElroy S L, Keck Jr P E.
Pharmacologic agents for the treatment of acute bipolar mania.
Biol Psychiatry.
2000;
48(6)
539-557
- 115
Ketter T A, Flockhart D A, Post R M, Denicoff K, Pazzaglia P J, Marangell L B, George M S,
Callahan A M.
The emerging role of cytochrome P450 3A in psychopharmacology.
J Clin Psychopharmacol.
1995;
15(6)
387-398
- 116
DeVane C L.
Pharmacogenetics and drug metabolism of newer antidepressant agents.
J Clin Psychiatry.
1994;
55 Suppl
38-45
- 117
Pollok B.
Recent developments in drug metabolism of relevance to psychiatrists.
Harvard Rev Psychiatry.
1994;
55 (12)
38-45
- 118
Meyer M C, Baldessarini R J, Goff D C, Centorrino F.
Clinically significant interactions of psychotropic agents with antipsychotic drugs.
Drug Saf.
1996;
15(5)
333-346
- 119
Goff D C, Baldessarini R J.
Drug interactions with antipsychotic agents.
J Clin Psychopharmacol.
1993;
13(1)
57-67
- 120
Monaco F, Cicolin A.
Interactions between anticonvulsant and psychoactive drugs.
Epilepsia.
1999;
40 Suppl 10
71-76
- 121
Prior T I, Chue P S, Tibbo P, Baker G B.
Drug metabolism and atypical antipsychotics.
Eur Neuropsychopharmacol.
1999;
9(4)
301-309
- 122
Wong Y W, Yeh C, Thyrum P T.
The effects of concomitant phenytoin administration on the steady-state pharmacokinetics
of quetiapine.
J Clin Psychopharmacol.
2001;
21(1)
89-93
- 123
Lucas R A, Gilfillan D J, Bergstrom R F.
A pharmacokinetic interaction between carbamazepine and olanzapine: observations on
possible mechanism.
Eur J Clin Pharmacol.
1998;
54(8)
639-643
- 124
Wilson W H.
Do anticonvulsants hinder clozapine treatment?.
Biol Psychiatry.
1995;
37(2)
132-133
- 125
Risby E D, Epstein C M, Jewart R D, Nguyen B V, Morgan W N, Risch S C, Thrivikraman K V,
Lewine R L.
Clozapine-induced EEG abnormalities and clinical response to clozapine.
J Neuropsychiatry Clin Neurosci.
1995;
7(4)
466-470
- 126
Arana G W, Goff D C, Friedman H, Ornsteen M, Greenblatt D J, Black B, Shader R I.
Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic
symptoms?.
Am J Psychiatry.
1986;
143(5)
650-651
- 127
Kahn E M, Schulz S C, Perel J M, Alexander J E.
Change in haloperidol level due to carbamazepine - a complicating factor in combined
medication for schizophrenia.
J Clin Psychopharmacol.
1990;
10(1)
54-57
- 128
Centorrino F, Baldessarini R J, Flood J G, Kando J C, Frankenburg F R.
Relation of leukocyte counts during clozapine treatment to serum concentrations of
clozapine and metabolites.
Am J Psychiatry.
1995;
152(4)
610-612
- 129
Junghan U, Albers M, Woggon B.
Increased risk of hematological side-effects in psychiatric patients treated with
clozapine and carbamazepine?.
Pharmacopsychiatry.
1993;
26(6)
262
- 130
Jerling M, Lindstrom L, Bondesson U, Bertilsson L.
Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine:
evidence from a therapeutic drug monitoring service.
Ther Drug Monit.
1994;
16(4)
368-374
- 131
Raitasuo V, Lehtovaara R, Huttunen M O.
Carbamazepine and plasma levels of clozapine.
Am J Psychiatry.
1993;
150(1)
169
- 132
Bourgeois B FD.
Pharmacological interactions between valproate and other drugs.
Am J Med.
1988;
84
9-33
- 133
Balfour J A, Bryson H M.
Valproid acid: a review of its pharmacology and therapeutic potential in indications
other than epilepsy.
CNS Drugs.
1994;
2
144-173
- 134
Kando J C, Tohen M, Castillo J, Centorrino F.
Concurrent use of clozapine and valproate in affective and psychotic disorders.
J Clin Psychiatry.
1994;
55(6)
255-257
- 135
Finley P, Warner D.
Potential impact of valproic acid therapy on clozapine disposition.
Biol Psychiatry.
1994;
36(7)
487-488
- 136
Centorrino F, Baldessarini R J, Kando J, Frankenburg F R, Volpicelli S A, Puopolo P R,
Flood J G.
Serum concentrations of clozapine and its major metabolites: effects of cotreatment
with fluoxetine or valproate.
Am J Psychiatry.
1994;
151(1)
123-125
- 137 Emrich M, Okuma T, Muller A A. Anticonvulsants in affective disorders. Amsterdam:
Excerpta Medica 1984
- 138
Loudon J B, Waring H.
Toxic reactions to lithium and haloperidol.
Lancet.
1976;
2(7994)
1088
- 139
Jeffries J, Remington G, Wilkins J.
The question of lithium/neuroleptic toxicity.
Can J Psychiatry.
1984;
29(7)
601-604
- 140
Goldney R D, Spence N D.
Safety of the combination of lithium and neuroleptic drugs.
Am J Psychiatry.
1984;
29
601-604
- 141
Schou M.
Long-lasting neurological sequelae after lithium intoxication.
Acta Psychiatr Scand.
1984;
70(6)
594-602
- 142
Addonizio G, Susman V L, Roth S D.
Neuroleptic malignant syndrome: review and analysis of 115 cases.
Biol Psychiatry.
1987;
22(8)
1004-1020
- 143
Blake L M, Marks R C, Luchins D J.
Reversible neurologic symptoms with clozapine and lithium.
J Clin Psychopharmacol.
1992;
12(4)
297-299
- 144
Baldessarini R J, Stephens J H.
Lithium carbonate for affective disorders. I. Clinical pharmacology and toxicology.
Arch Gen Psychiatry.
1970;
22(1)
72-77
- 145
Garcia G, Crismon M L, Dorson P G.
Seizures in two patients after the addition of lithium to a clozapine regimen.
J Clin Psychopharmacol.
1994;
14(6)
426-428
- 146
Berk M.
Lamotrigine and the treatment of mania in bipolar disorder.
Eur Neuropsychopharmacol.
1999;
9 Suppl 4
119-123
- 147
Normann C, Langosch J, Schaerer L O, Grunze H, Walden J.
Treatment of acute mania with topiramate.
Am J Psychiatry.
1999;
156(12)
2014
- 148
Ketter T A, Frye M A, Cora-Locatelli G, Kimbrell T A, Post R M.
Metabolism and excretion of mood stabilizers and new anticonvulsants.
Cell Mol Neurobiol.
1999;
19(4)
511-532
- 149
Patsalos P N, Duncan J S.
New antiepileptic drugs: a review of their current status and clinical potential.
CNS Dugs.
1994;
2
40-77
- 150
Anderson G D, Graves N M.
Drug interactions with anti-epileptic agents. Prevention and management.
CNS Drugs.
1994;
2
268-279
- 151
Alldredge B K.
Seizure risk with psychotropic drugs: clinical and pharmacokinetic considerations.
Neurology.
1999;
53 (Suppl. 2)
68-75
- 152
Sproule B A, Naranjo C A, Brenmer K E, Hassan P C.
Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review
of the evidence.
Clin Pharmacokinet.
1997;
33(6)
454-471
Prof. Dr. Ch. Barnas
Klinische Abteilung für Allgemeine Psychiatrie · Univ.-Klinik für Psychiatrie
Währinger Gürtel 18-20
1090 Wien
Österreich
